Russia’s latest VED/SSM list update is a reminder that “generic timing” is no longer just a U.S. or EU exercise—it’s a global discipline. The market isn’t waiting for your internal calendar. It’s moving to the rhythm of patent expirations, regulatory s…

Pharma pipelines don’t fail in the lab. They fail in the courtroom.
That’s the uncomfortable truth behind Freedom to Operate (FTO) work—and why the best teams treat it like a core operating system, not a last-minute legal checkbox.
If you’re building a…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Competitive Advantage
Most pharma conversations about generics start with a familiar script: ANDA this, exclusivity that, patent dance over there. But if you’re building a differentiated p…

Pharma IP teams are used to thinking in “years” and “filings.” But in Russia right now, the clock is moving in ways that can quietly—and permanently—change the value of a portfolio.
Here’s the agitation: if your team is still treating Russia patent ter…

Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
In pharma, “patent strategy” is often treated like a paperwork exercise: file early, draft broadly, hope for the best. But the market doesn’t reward hope. …

Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical supply chain, the most valuable “deadline” isn’t a clinical trial milestone or a formulary committee meeting. It’s patent expiration. And the real le…

Most teams don’t “forecast” generic launches—they guess.
And guessing is expensive.
If you’re in strategy, BD, pricing, or competitive intelligence, you already know the stakes: the first generic to launch can reshape revenue, market share, contracti…

Most people “hunt” patents the wrong way. Here’s the faster playbook.
If you’re trying to find the real talent behind drug innovation—patent inventors, assignees, and the teams quietly building the next wave—there’s a trap: you search for companies, th…

Biotech investors love “pipeline quality.” But portfolio winners are often built on something less glamorous: how you rank projects when capital is scarce and timelines are uncertain.
That’s where two finance concepts—Net Present Value (NPV) and the Pr…

Biopharma’s “patent cliff” isn’t just a revenue story—it’s a talent story.
When patents expire, the obvious headlines follow: generic competition, margin compression, pipeline triage. But there’s a quieter shift happening in parallel—one that recruit…